Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-Treated Patients With BRAFV600-mutated Metastatic Melanoma
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-0720
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2019
Authors
Publisher
American Association for Cancer Research (AACR)